Pluristem Therapeutics Inc. (PSTI)

3.80
0.01 0.14
NASDAQ : Health Technology
Prev Close 3.79
Open 3.80
Day Low/High 3.80 / 3.80
52 Wk Low/High 3.24 / 13.80
Volume 1.04K
Avg Volume 306.50K
Exchange NASDAQ
Shares Outstanding 15.31M
Market Cap 59.72M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem And Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation

Pluristem And Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation

In Parallel Pluristem and Case Western University Announce Early Data on PLX-R18 in Umbilical Cord Blood Transplantation

Pluristem To Present At Two Cell Therapy Conferences In January 2015

Pluristem To Present At Two Cell Therapy Conferences In January 2015

Presentations Focus on Delivery of Cell Therapy From Manufacturing Facility to Patient Bedside Aided by Company's Proprietary Point-of-Care Cell Thawing Device

Pluristem Granted Patent For Foundational Cell Harvesting Technology In South Africa

Pluristem Granted Patent For Foundational Cell Harvesting Technology In South Africa

Patent Covers Methods for Using Vibration to Harvest Large Yields of Viable Cells Grown With Three-Dimensional Technology

New Published Data Show Pluristem's PLX Cells Protect Neurons

New Published Data Show Pluristem's PLX Cells Protect Neurons

PLX Cells Could Potentially be Used to Treat Stroke or Other Injuries to the Nervous System Attributable to Low Oxygen Levels

Pluristem's Dr. Ohad Karnieli To Present At Two Upcoming Scientific Conferences

Pluristem's Dr. Ohad Karnieli To Present At Two Upcoming Scientific Conferences

Presentations to Focus on Pluristem's Industry-Leading Expertise in 3D Cell Culturing and Cell Expansion Technologies

Pluristem Granted Patents In Australia And New Zealand For Use Of Placental Cells In The Treatment Of Multiple Indications

Pluristem Granted Patents In Australia And New Zealand For Use Of Placental Cells In The Treatment Of Multiple Indications

Indications Include Orthopedic, Nerve Injury and Neurodegenerative Diseases

Case Western Reserve University To Study Pluristem's PLX-RAD Cells In Umbilical Cord Blood Transplants For The Treatment Of Blood Cancers And Genetic Diseases

Case Western Reserve University To Study Pluristem's PLX-RAD Cells In Umbilical Cord Blood Transplants For The Treatment Of Blood Cancers And Genetic Diseases

The Study Will Determine Whether Pluristem's Second Major Product Line May Help Cord Blood Cells to Successfully Replace Damaged Bone Marrow

Pluristem Advances Its Second Major Cell Therapy Product Line From Development To Large-Scale Manufacturing

Pluristem Advances Its Second Major Cell Therapy Product Line From Development To Large-Scale Manufacturing

Marks Second Major Cell Therapy Product Line Developed on Company's PLX Platform; PLX-RAD Cells Address Multiple Indications Associated With Bone Marrow Deficiency

Pluristem To Deliver Scientific Presentations At 3rd International Placenta Stem Cell Society Meeting

Pluristem To Deliver Scientific Presentations At 3rd International Placenta Stem Cell Society Meeting

Sharing Insights and Knowledge of the Unique Immune-Privileged Properties and Mechanism of Action of PLX Cells

Israel's Ministry Of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used At Its New Haifa Facility

Israel's Ministry Of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used At Its New Haifa Facility

This Follows Clearances From U.S., E.U., German, and South Korean Regulators

Pluristem To Host Investor Breakfast And Webcast On July 23 In New York City

Pluristem To Host Investor Breakfast And Webcast On July 23 In New York City

Key Opinion Leader Dr. Baha Sibai Will Discuss Preeclampsia, a Disease That Costs the U.S. $7 Billion Annually

Pluristem Initiates South Korean Arm Of Multinational Phase II Intermittent Claudication Trial

Pluristem Initiates South Korean Arm Of Multinational Phase II Intermittent Claudication Trial

Trial Now Active in 13 Clinical Centers in 4 Countries

Pluristem's Ohad Karnieli To Deliver A Plenary Presentation On Cell Therapy Manufacturing At ISUS 2014 Conference

Pluristem's Ohad Karnieli To Deliver A Plenary Presentation On Cell Therapy Manufacturing At ISUS 2014 Conference

Pluristem to Share Insights on Emerging Markets and Its Industry-Leading Cell Manufacturing Methods With Audience of Bio-Manufacturing Experts

Pluristem Selects Rotator Cuff Repair As New Orthopedic Indication

Pluristem Selects Rotator Cuff Repair As New Orthopedic Indication

PLX Cells Offer Potential as First Off-the-Shelf Product for Muscle and Tendon Regeneration

Pluristem Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells

Pluristem Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells

PLX Cells Shown to be a Potentially Effective Treatment

Pluristem Move Forward In The Orthopedic Area With The Support Of Key Opinion Leaders

Pluristem Move Forward In The Orthopedic Area With The Support Of Key Opinion Leaders

Evaluating Several Orthopedic Indications for Company's PLX-PAD Cell Therapy

TheStreet Quant Rating: D- (Sell)